Le peu, le très peu que lon peut faire, il faut le faire quand même. Théodore Monod(1902-2000)
Platynereis dumerili
Depuis le 18-09-2006 :
189755 visiteurs
Depuis le début du mois :
3918 visiteurs
Billets :
776 billets
La Commission européenne a donné son feu vert au
financement d'un registre européen de lignées de cellules souches
embryonnaires humaines, jeudi 29 mars ...
Bientôt un site Internet avec des informations sur les essais
10 Etats membres de l'UE sont associés
On
entend par "lignée de cellules souches embryonnaires humaines" une
culture de cellules souches isolées à partir d'un embryon humain à un
stade précoce, ces cellules pouvant être multipliées à l'infini en
laboratoire. ...
http://www.la-croix.com/article/index.jsp?docId=2299059&rubId=5547
Publié par trichard à 11:14:10 dans BIOSOPHIE | Commentaires (0) | Permaliens
La France, troisième consommateur mondial de pesticides
Confusion et collusion des intérêts
Les
deux auteurs ont mené une étude fine de ces hommes qui ont fait
l'agriculture française après la guerre. Les objectifs éminemment
louables de l'autosuffisance alimentaire inciteront à s'engouffrer sur
la voie de l'agriculture intensive : tous travailleront main dans la
main au service de la cause commune, les services du ministère de
l'agriculture, notamment le service de la protection des végétaux et la
commission d'étude de la toxicité, les scientifiques de l'Inra et les
industriels dits « de la protection des plantes » qui développent les
engrais et les produits chimiques.
Très vite cette complicité se
transformera en confusion et collusion des intérêts, les mêmes hommes
clés se chargeant de concevoir les substances chimiques à mettre sur le
marché, de développer des variétés de plus en plus productives et en
même temps d'homologuer et d'étudier la toxicité de ces substances.
Dans
ce système, l'administration n'est plus à même de défendre l'intérêt
collectif, de garantir la protection de la santé et des milieux, et les
agriculteurs eux-mêmes sont loin de maîtriser les règles du jeu.
...
http://www.la-croix.com/article/index.jsp?docId=2298767&rubId=5547
Publié par trichard à 11:03:02 dans GEOSOPHIE | Commentaires (0) | Permaliens
|
References
Publié par trichard à 10:56:11 dans PHYSIOLOGIE | Commentaires (0) | Permaliens
John Whitfield
|
References
Publié par trichard à 10:43:44 dans PLANETOLOGIE | Commentaires (0) | Permaliens
|
Scientists
have discovered enzymes that can efficiently convert blood groups A, B
and AB into the 'universal' O group - which can be given to anyone but
is always in short supply.
The
two novel glycosidase enzymes were identified in bacteria by an
international team led by Henrik Clausen of the University of
Copenhagen in Denmark. The researchers hope that the enzymes will both
improve the erratic supplies of blood around the world, and also the
safety of transfusions. Clinical trials to test the safety and
effectiveness of their converted blood are being planned.
The
ABO blood-type system is based on the presence or absence of the
sugar-based antigens 'A' and 'B' on red blood cells. Type O blood cells
have neither A nor B antigens, so may be safely transfused into anyone.
But types A, B and AB blood do, and cause life-threatening immune
reactions if they are given to patients with a different blood group.
The bacterial glycosidase enzymes strip these antigens away from A, B
and AB blood.
The
idea of such antigen-stripping goes back to the early 1980s, with the
discovery of an enzyme in coffee beans that removes B antigens from red
blood cells.
Early-stage clinical trials showed that the converted blood could be
safely transfused into individuals of different blood groups; no traces
of enzyme or antigen remained to cause reactions. But the enzyme reaction was far too inefficient to make large-scale conversion practical.
Clausen's
team screened 2,500 extracts from different bacteria and fungi for
their ability to cleave off A and B antigens. The newly discovered
bacterial 'B' enzyme is nearly 1,000 times more efficient then the
coffee-bean B enzyme - the additional discovery of an enzyme to remove
A antigens means that all blood types can now be converted. The work is
reported in Nature Biotechnology.
Common stock
Type
O is the most common blood group, but stocks constantly run low because
it is used in all emergency situations where there is no time to
determine the patient's own group.
An
additional pressure on type-O blood, particularly in the United States,
comes from the mismatch between blood donors and recipients. Most US
donors are Caucasian, amongst whom 45% of people are blood group O. But
more than half of African Americans, and nearly all native Americans
are O, and so require type-O blood.
Also
the donor population is shrinking as fears of transfusion-transmitted
infections of new diseases such as SARS, mad-cow disease and West Nile
disease remove from the pool donors who may have been exposed.
"Restrictions
are getting almost comical," says Martin Olsson, head of the Lund
University Hospital Blood Centre in Sweden, and a member of the
international team. "At different times, the US excluded from donation
those who had recently visited Europe in case they had contact with
BSE, and Europe has excluded those who recently visited the US where
they perceive a higher risk of HIV."
Yet in practice the greatest risk in blood transfusion is
not the transmission of disease but the accidental transfusion of the
wrong blood group, he says. "As a clinician, I see the biggest
advantage of the new enzyme technology as eliminating incidents of
giving the wrong blood."
The
Boston-based company ZymeQuest is developing the enzyme technology for
commercial use in blood centres. Early-stage clinical trials are
underway. If all goes well, blood centres could be using the
technologies in just a few years.
http://www.la-croix.com/article/index.jsp?docId=2299267&rubId=5547
Publié par trichard à 10:32:04 dans PHYSIOLOGIE | Commentaires (0) | Permaliens